The Labidi-Galy Lab

From pathogenesis to precision medicine in breast and ovarian cancer

In the last decade, large-scale next-generation sequencing of DNA and RNA allowed a new comprehension of cancer. Cancer cells are characterized by specific genomic alterations that include multiple gene mutations, amplifications and/or deletions. They interact with different components of the tumor microenvironment such as immune cells, fibroblasts and endothelial cells. We are committed to precision medicine by combining our knowledge about the genomic alterations of cancer cells and the immune composition of the tumor microenvironment in order to develop new therapies. We use digital pathology, multispectral immunohistochemistry, laser capture microdissection and next-generation sequencing to reach our goal.

The lab’s research is strongly oriented toward translation of our findings into diagnostic and therapeutic tools to improve the lives of women with breast and ovarian cancer.



BRCA1/BRCA2 mutations in breast and ovarian cancer

Germline mutations of BRCA1/BRCA2 genes occur in up to 5% of breast cancer patients and 15% of ovarian cancers. These genes are major players in the repair of DNA double strand breaks. BRCA carriers have therefore increased sensitivity to DNA-damaging agents, such as platinum or PARP inhibitors. We recently showed a correlation between the BRCA2 genotype and response to platinum in ovarian cancer patients. Only BRCA2 carriers, harboring mutations located in the RAD51-binding domain (RAD51-BD), have prolonged treatment-free intervals and longer survival, whereas the other BRCA2 carriers did not show a survival benefit. We are currently investigating the impact of BRCA mutations on toxicity and response to chemotherapy in breast cancer patients.

Read more

Tumor microenvironment of triple-negative breast cancer

 Tumorectomy of TNBC

Sub-characterization of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment

 Mutiplex IHC on triple-negative breast cancer

Ovarian cancer

Progression from p53 signature to STIC to high-grade serous carcinoma.

Clinical address

Hôpitaux Universitaires de Genève

Department of Oncology

Rue Gabrielle Perret-Gentil 4,

1205, Genève, Switzerland

Tel: +41 22 372 40 14

Contact information

Dr Intidhar Labidi-Galy, MD, PhD


Research lab address

Centre Medico-Universitaire, UNIGE

6th floor, Room A06.2910a

Rue Michel Servet 1,

1206, Genève, Switzerland

Office: +41 22 379 54 82

Lab: +41 22 379 52 89